SMA
JSPR icon

Sage Mountain Advisors’s Jasper Therapeutics JSPR Stock Holding History

Sage Mountain Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,570
Closed -$355K – 585
2021
Q2 		$355K Hold
3,570
– – 0.06% 288
2021
Q1 		$353K Hold
3,570
– – 0.08% 208
2020
Q4 		$357K Buy
+3,570
New +$355K 0.12% 118

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sage Mountain Advisors's JSPR Position: Q3 2021 in Review

Sage Mountain Advisors sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 3,570 shares — an estimated $355K sold.

Sage Mountain Advisors first reported a position in JSPR in Q4 2020 and held it in 3 quarters. The position peaked at $357K in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • Sage Mountain Advisors reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sage Mountain Advisors sold 3,570 Jasper Therapeutics shares in Q3 2021, an estimated $355K.
  • Sage Mountain Advisors first reported a position in Jasper Therapeutics in Q4 2020 and held it in 3 quarters.
  • Sage Mountain Advisors's Jasper Therapeutics position peaked at $357K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Sage Mountain Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.